New therapies for lung cancer

Study points to potential new therapies for hard-to-treat lung cancers

March 5, 2026
8:41 pm

Findings from a study led by researchers at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James) support the potential of new therapies that could improve clinical outcomes for patients with squamous and adenocarcinoma non-small cell lung cancers (NSCLC) that don't respond to immunotherapy.

The researchers say their study provides strong evidence for the possible effectiveness of therapies that target both lysosomes (particles in cells that help maintain cellular stability and nutrient availability) and a protein called SREBP-1 that increases glucose uptake and helps tumors resist current therapies that inhibit lysosomes.

Corresponding and senior author for the study was Deliang Guo, Ph.D., founding director of the Center for Cancer Metabolism at the OSUCCC–James. Yaogang Zhong, Ph.D., a senior researcher in Guo’s lab, was the first author.

Study points to potential new therapies for hard-to-treat lung cancers

Sign up for Blog Updates